Baird Financial Group Inc. Raises Stake in Astera Labs, Inc. $ALAB

Baird Financial Group Inc. increased its position in shares of Astera Labs, Inc. (NASDAQ:ALAB) by 799.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 40,481 shares of the company’s stock after acquiring an additional 35,981 shares during the quarter. Baird Financial Group Inc.’s holdings in Astera Labs were worth $3,660,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Straight Path Wealth Management raised its stake in Astera Labs by 1.5% during the second quarter. Straight Path Wealth Management now owns 6,850 shares of the company’s stock worth $619,000 after purchasing an additional 100 shares during the period. First Horizon Advisors Inc. increased its holdings in shares of Astera Labs by 12.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 982 shares of the company’s stock worth $89,000 after buying an additional 108 shares during the last quarter. Advisors Asset Management Inc. increased its holdings in shares of Astera Labs by 68.6% during the 2nd quarter. Advisors Asset Management Inc. now owns 477 shares of the company’s stock worth $43,000 after buying an additional 194 shares during the last quarter. Berbice Capital Management LLC raised its position in shares of Astera Labs by 14.3% during the 2nd quarter. Berbice Capital Management LLC now owns 1,600 shares of the company’s stock valued at $145,000 after buying an additional 200 shares during the period. Finally, Wealthcare Advisory Partners LLC lifted its holdings in Astera Labs by 0.8% in the second quarter. Wealthcare Advisory Partners LLC now owns 29,160 shares of the company’s stock valued at $2,637,000 after acquiring an additional 221 shares during the last quarter. 60.47% of the stock is currently owned by institutional investors and hedge funds.

Astera Labs Price Performance

Shares of NASDAQ ALAB opened at $164.32 on Thursday. The business has a 50-day moving average of $168.38 and a two-hundred day moving average of $152.69. The company has a market capitalization of $27.75 billion, a price-to-earnings ratio of 148.04, a price-to-earnings-growth ratio of 3.11 and a beta of 1.51. Astera Labs, Inc. has a 1 year low of $47.13 and a 1 year high of $262.90.

Astera Labs (NASDAQ:ALAB) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.10. The business had revenue of $230.58 million for the quarter, compared to the consensus estimate of $206.42 million. Astera Labs had a return on equity of 13.48% and a net margin of 27.50%.The business’s revenue for the quarter was up 103.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.23 EPS. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. As a group, equities research analysts expect that Astera Labs, Inc. will post 0.34 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Manuel Alba sold 150,000 shares of the company’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $166.18, for a total value of $24,927,000.00. Following the completion of the transaction, the director owned 1,574,498 shares in the company, valued at approximately $261,650,077.64. This represents a 8.70% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Michael Truett Tate sold 11,430 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of $144.69, for a total transaction of $1,653,806.70. Following the completion of the transaction, the chief financial officer directly owned 192,297 shares in the company, valued at $27,823,452.93. This trade represents a 5.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 586,936 shares of company stock valued at $89,331,140 over the last three months. 12.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on ALAB shares. Morgan Stanley reissued an “overweight” rating and set a $210.00 target price on shares of Astera Labs in a research note on Wednesday, December 3rd. BNP Paribas Exane started coverage on Astera Labs in a report on Thursday, November 20th. They set an “outperform” rating and a $225.00 price target for the company. Raymond James Financial initiated coverage on Astera Labs in a research report on Friday, November 21st. They set a “hold” rating for the company. Citigroup reaffirmed an “outperform” rating on shares of Astera Labs in a research report on Tuesday. Finally, Cowen reaffirmed a “hold” rating on shares of Astera Labs in a research note on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $188.17.

About Astera Labs

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.